Evidence map›Paper›PMID 38153686›Full record

ReviewCurrent treatment options in oncology2023

Treatment Landscape of Renal Cell Carcinoma.

Yu-Wei Chen, Luke Wang, Justine Panian, Sohail Dhanji, Ithaar Derweesh, Brent Rose, Aditya Bagrodia, Rana R McKay

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current treatment options in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 2 pooled it
27.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 2 syntheses or guidelines pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. A radiogenomics biomarker based on tumor angiogenesis for non-invasive prognosis of clear cell renal cell carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Review

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yu-Wei ChenDivision of Hematology Oncology, University of California San Diego, San Diego, CA, USA.
Luke WangDepartment of Urology, University of California San Diego, San Diego, CA, USA.
Justine PanianSchool of Medicine, University of California San Diego, San Diego, CA, USA.
Sohail DhanjiDepartment of Urology, The University of Tennessee Health Science Center, Memphis, TN, USA.
Ithaar DerweeshDepartment of Urology, University of California San Diego, San Diego, CA, USA.
Brent RoseDepartment of Radiation Oncology, University of California San Diego, San Diego, CA, USA.
Aditya BagrodiaDepartment of Urology, University of California San Diego, San Diego, CA, USA.
Rana R McKayDivision of Hematology Oncology, University of California San Diego, San Diego, CA, USA. rmckay@health.ucsd.edu.
University of California, San Diego · USUniversity of Tennessee Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementThe treatment landscape of renal cell carcinoma (RCC) has evolved significantly over the past three decades. Active surveillance and tumor ablation are alternatives to extirpative therapy in appropriately selected patients. Stereotactic body radiation therapy (SBRT) is an emerging noninvasive alternative to treat primary RCC tumors. The advent of immune checkpoint inhibitors (ICIs) has greatly improved the overall survival of advanced RCC, and now the ICI-based doublet (dual ICI-ICI doublet; or ICI in combination with a vascular endothelial growth factor tyrosine kinase inhibitor, ICI-TKI doublet) has become the standard frontline therapy. Based on unprecedented outcomes in the metastatic with ICIs, they are also being explored in the neoadjuvant and adjuvant setting for patients with high-risk disease. Adjuvant pembrolizumab has proven efficacy to reduce the risk of RCC recurrence after nephrectomy. Historically considered a radioresistant tumor, SBRT occupies an expanding role to treat RCC with oligometastasis or oligoprogression in combination with systemic therapy. Furthermore, SBRT is being investigated in combination with ICI-doublet in the advanced disease setting. Lastly, given the treatment paradigm is shifting to adopt ICIs at earlier disease course, the prospective studies guiding treatment sequencing in the post-ICI setting is maturing. The effort is ongoing in search of predictive biomarkers to guide optimal treatment option in RCC.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsAdjuvants, ImmunologicAngiogenesis InhibitorsHumansNeoplasm Recurrence, LocalProspective StudiesVascular Endothelial Growth Factor AAdjuvants, ImmunologicAngiogenesis InhibitorsVascular Endothelial Growth Factor AImmune checkpoint inhibitorImmunotherapyKidney cancerRenal cell carcinoma

Identifiers

PMID38153686
PMCPMC10781877
OpenAlexW4390345332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.